Moreover, BC patients from the IMvigor210 cohort, who had objective responses to anti-PD-L1 treatment, had remarkably decreased expressions of TPST1 and EMP1, the suppressed expressions of which might improve the treatment response of the monoclonal antibody atezolizumab. The gene discussed is TPST1; the disease is breast cancer.